BioCardia, Inc. (NASDAQ:BCDA) Expected to Announce Earnings of -$0.23 Per Share

Wall Street brokerages expect BioCardia, Inc. (NASDAQ:BCDAGet Rating) to report earnings of ($0.23) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for BioCardia’s earnings, with the lowest EPS estimate coming in at ($0.40) and the highest estimate coming in at ($0.10). BioCardia posted earnings of ($0.20) per share in the same quarter last year, which indicates a negative year over year growth rate of 15%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioCardia will report full year earnings of ($0.72) per share for the current financial year, with EPS estimates ranging from ($0.98) to ($0.44). For the next financial year, analysts forecast that the firm will report earnings of ($0.57) per share, with EPS estimates ranging from ($0.70) to ($0.44). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for BioCardia.

BioCardia (NASDAQ:BCDAGet Rating) last posted its quarterly earnings data on Tuesday, March 29th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. BioCardia had a negative return on equity of 98.68% and a negative net margin of 1,261.32%. During the same period in the prior year, the business posted ($0.16) earnings per share.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of BioCardia from a “sell” rating to a “hold” rating in a research note on Monday, April 11th. Brookline Capital Management reissued a “buy” rating on shares of BioCardia in a research note on Thursday, February 3rd.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC purchased a new position in BioCardia during the 1st quarter worth $28,000. Vanguard Group Inc. increased its position in shares of BioCardia by 57.9% during the 1st quarter. Vanguard Group Inc. now owns 650,523 shares of the company’s stock valued at $1,346,000 after purchasing an additional 238,554 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in BioCardia in the first quarter worth about $57,000. Commonwealth Equity Services LLC boosted its stake in BioCardia by 18.1% in the first quarter. Commonwealth Equity Services LLC now owns 49,978 shares of the company’s stock valued at $103,000 after acquiring an additional 7,671 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of BioCardia during the 4th quarter valued at approximately $109,000. Hedge funds and other institutional investors own 15.40% of the company’s stock.

BioCardia stock opened at $1.40 on Thursday. The firm has a market cap of $24.43 million, a price-to-earnings ratio of -1.84 and a beta of 1.40. BioCardia has a 52-week low of $1.10 and a 52-week high of $5.10. The firm has a 50 day moving average price of $1.82 and a two-hundred day moving average price of $2.00.

BioCardia Company Profile (Get Rating)

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.

Further Reading

Get a free copy of the Zacks research report on BioCardia (BCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.